One Capital Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,424 shares of the biopharmaceutical company’s stock after buying an additional 4,968 shares during the quarter. One Capital Management LLC’s holdings in Pfizer were worth $3,264,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after purchasing an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after purchasing an additional 2,028,313 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 3.2% in the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after purchasing an additional 1,085,437 shares in the last quarter. Finally, LSV Asset Management raised its holdings in shares of Pfizer by 0.6% in the 2nd quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock valued at $1,117,726,000 after purchasing an additional 199,100 shares in the last quarter. Institutional investors own 69.75% of the company’s stock.
PFE has been the subject of several recent research reports. Jefferies Group set a $37.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, September 18th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Tuesday, October 3rd. Finally, ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $38.83.
Pfizer Inc. (NYSE:PFE) opened at $36.54 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $37.35. The stock has a market cap of $217,800.00, a P/E ratio of 22.42, a PEG ratio of 2.44 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.61 EPS. research analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.72%. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 78.53%.
Pfizer announced that its board has authorized a stock repurchase program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.